ArticleActa biochimica Polonica2026
3-O-ethyl-L-ascorbic acid modulates pro-inflammatory cytokine and extracellular matrix-related biomarker levels in human lung fibroblasts: an
Article in Acta biochimica Polonica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
L-Ascorbic acid (also known as vitamin C) is widely used in dietary supplements and cosmetic formulations because of its antioxidant properties and critical role in numerous physiological processes. In this study, we investigated the effects of 3-O-ethyl-L-ascorbic acid (EAA), a stable vitamin C derivative, on inflammatory and extracellular matrix (ECM)-related biomarkers in MRC-5 human lung fibroblasts. We quantified protein levels of pro-inflammatory cytokines, ECM-associated proteins, and matrix-degrading enzymes using enzyme-linked immunosorbent assay (ELISA)-based assays. EAA treatment significantly reduced the basal levels of interleukin-1 Beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), indicating modulation of inflammatory signaling under unstimulated conditions. EAA also increased the levels of collagen type I (COL-I), collagen type III (COL-III), and hyaluronan synthase 2 (HAS2), suggesting enhanced production of ECM-associated components. In addition, EAA altered the levels of matrix-degrading enzymes in a time-dependent manner. Matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) exhibited a biphasic response characterized by higher levels at 24 h and lower levels at 48 h, whereas elastase levels were consistently reduced. Taken together, these findings suggest that EAA modulates inflammatory, ECM-associated, and ECM-degrading biomarker levels in MRC-5 fibroblasts under the tested
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.